A study of CAR-T therapy for newly diagnosed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a one-time cell therapy called ciltacabtagene autoleucel (a CAR-T treatment) in people who have newly diagnosed multiple myeloma and are not eligible for a stem cell transplant. It aims to see if this treatment is safe and effective as an early therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with multiple myeloma that is measurable in the blood or urine.
- You should not be a candidate for high-dose chemo with stem cell transplant due to age, other health conditions, or your choice to avoid it.
- You must have already received 3 to 5 cycles of initial drug therapy (like DRd, VRd, or DVRd) and have had a partial response or better.
- You need to be in good physical condition (ECOG score of 0 or 1) and willing to follow study guidelines.
- You cannot have significant frailty (score of 2 or more on a special geriatric assessment).
- You must not have certain ongoing side effects from earlier therapy or need constant oxygen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This study tests a new type of cell therapy, called CAR-T, for people newly diagnosed with myeloma who can't have a stem cell transplant. The therapy uses your own immune cells, changed in a lab to better fight the myeloma cells.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.